Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma

Blood Transfusion

Volumn 6, Issue 1, 2008, Pages 25-36

  Liumbruno, Giancarlo Maria ^a,c   Sodini, Maria Laura ^a   Grazzini, Giuliano ^b  

^a Servizio di Immunoematologia e Medicina Trasfusionale   (Italy)

^b Centro Regionale di Coordinamento e Compensazione   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DETERGENT; FRESH FROZEN PLASMA; SOLVENT;

ALLERGIC REACTION; APHERESIS; BACTERIUM DETECTION; BLOOD ANALYSIS; BLOOD FILTRATION; BLOOD TRANSFUSION; CLINICAL PRACTICE; EVIDENCE BASED PRACTICE; FEVER; HEMODILUTION; HUMAN; IMMUNE DEFICIENCY; METHODOLOGY; PATIENT SAFETY; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT INDICATION;

BLOOD COMPONENT TRANSFUSION; DISINFECTION; HUMANS; ITALY; PLASMA; PRACTICE GUIDELINES AS TOPIC;

EID: 47749155632     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0027-07     Document Type: Review

References (152)

1. Gonzalez M, Règine V, Piccinini V, et al. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy. Transfusion 2005; 45: 1670-5.
2. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005; 19: 110-26.
3. Blajchman MA, Beckers EAM, Dickmeiss E, et al. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005; 19: 259-72.
4. Stainsby D, Jones H, Asher D, et al. Serious Hazards of Transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006; 20: 273-82.
5. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma: in search of a zero-risk blood supply. JAMA 1994; 272: 1210-4.
6. Jakson BR, AuBuchon JP, Birkmeyer JD. Update of cost-effectiveness analysis for solvent-detergent-treated plasma [letter]. JAMA 1999; 282: 329.
7. Bianco C. Choice of human plasma for transfusion. Transfus Med Rev 1999; 13: 84-8.
8. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 1999; 39: 479-87.
9. Pereira A. Cost-effectiveness analysis and the selection of blood products. Curr Opin Hematol 2000; 7: 420-5.
10. Hoots WK. History of plasma-product safety. Transfus Med Rev 2001; 15 (Suppl 1): 3-10.
11. Van Hulst M, de Wolf JTM, Staginnus U, et al. Pharmacoeconomics of blood transfusion safety: review of the available evidence. Vox Sang 2002; 83: 146-55.
12. Wilson K, Hébert PC. The challenge of an increasingly expensive blood system. Can Med Assoc J 2003; 168: 1149-50.
13. Riedler GF, Haycox AR, Duggan AK, et al. Solvent-detergent-treated plasma may be cost-effective [letter]. Vox Sang 2003; 84: 331.
14. Riedler GF, Haycox AR, Duggan AK, et al. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003; 85: 88-95.
15. Field MJ, Lohr KN. Guidelines for Clinical Practice: from Development to Use, Washington, DC, Institute of Medicine, National Academy Press; 1992.
16. Agenzia per i Servizi Sanitari Regionali. Programma Nazionale per le Linee Guida - Manuale Metodologico, Milano, Italia, Arti Grafiche Passoni srl; 2002. Available at: http://www.pnlg.it/doc/Manuale_PNLG.pdf.
17. Guyatt G, Schünemann HJ, Cook D, et al. Applying the grades of recommendation for antithrombotic and thrombolytic therapy. Chest 2004; 126:179S-87S.
18. Horowitz B, Wiebe ME, Lippin A, et al. Inactivation of viruses in labile blood derivatives: disruption of lipid-enveloped viruses by tri(n-butyl) phosphate detergent combinations. Transfusion 1985; 25: 516-22.
19. Sharma AD, Sreeram D, Erb T, et al. Solvent-detergent fresh frozen plasma. A superior alternative to standard fresh frozen plasma? J Cardiothorac Vasc Anesth 2000; 14: 712-7.
20. American Society of Anesthesiologists Task Force on Blood Component Therapy. Practice Guidelines for blood component therapy. Anesthesiology 1996; 84: 732-47.
21. Calder L, Hebert PC, Carter AO, et al. Review of published recommendations and guidelines for the transfusions of allogeneic red blood cells and plasma. Can Med Assoc J 1997; 156 (11 Suppl): S1-8.
22. Marconi M: Italian guidelines for the appropriate use of plasma. Tumori 2001; 87: S14-6.
23. Hellstern P, Muntean W, Schramm W, et al. Practical guidelines for the clinical use of plasma Thromb Res 2002; 107: S53-7.
24. Practice Guidelines for Blood Transfusion: A Compilation from Recent Peer-Reviewed Literature. American Red Cross 2002. Available at: http://chapters.redcross.org/br/indianaoh/hospitals/transfusion_guidelines.htm. re.
25. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28.
26. Horowitz B, Lazo A, Grossberg H, et al. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 1998; 74 (Suppl 1): 203-6.
27. Biesert L, Suhartono H. Solvent/detergent treatment of human plasma - a very robust method for virus inactivation. Validated virus safety of OCTAPLASâ. Vox Sang 1998; 74 (Suppl 1): 207-12.
28. Mohr H. Virus inactivation of fresh plasma. Vox Sang 1998; 74 (Suppl 2): 171-2.
29. Rollag H, Solheim BG, Svennevig JL. Viral safety of blood derivatives by immune neutralization. Vox Sang 1998; 74 (Suppl 1): 213-7.
30. Solheim BG, Rollag H, Svennevig JL, et al. Viral safety of solvent/detergent-treated plasma. Transfusion 2000; 40: 84-90.
31. Guertler LG. Virus safety of human blood, plasma, and derived products. Thromb Res 2002; 107: S39-45.
32. Hellstern P, Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 2002; 107 (Suppl 1): S3-8.
33. Horowitz B. Pathogen inactivated transfusion plasma: existing and emerging methods. Vox Sang 2002; 83 (Suppl 1): 429-36.
34. Bianco C. Choice of human plasma preparations for transfusion. Vox Sang 2002; 83 (Suppl 1): 437-41.
35. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004; 11: 346-50.
36. Remington KM, Trejo SR, Buczynski G, et al. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox Sang 2004; 87: 10-8.
37. Klein HG. Pathogen inactivation technology: cleansing the blood supply. J Intern Med 2005; 257: 224-37.
38. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006; 35: 83-90.
39. Seghatchian J, de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006; 35: 189-96.
40. Hoots K, Canty D. Clotting factor concentrates and immune function in haemophilic patients. Haemophilia 1998; 4: 704-13.
41. Ghio M, Contini P, Ottonello L, et al. Effects of clotting factors concentrates on lymphocyte and neutrophil function in vitro. Thromb Haemost 2003; 89: 365-73.
42. Balkan C, Kavakli K, Kutukcluler N, et al. The effect of clotting factor concentrates on the immune system in HIV-negative haemophilics. Haemophilia 2005; 11: 366-70.
43. Gazzetta Ufficiale del 13/04/05 N. 85, Decreto Legislativo 3 Marzo 2005: "Caratteristiche e modalità per la donazione di sangue e di emocomponenti".
44. th ed, Strasbourg, Council of Europe Press; 2006.
45. George JN, Pickett EB, Heinz R. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood 1986; 68: 307-9.
46. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006; 20: 1-26.
47. Greenwalt TJ. The how and why of exocytic vesicles. Transfusion 2006; 46: 143-52.
48. Ratko TA, Cummings JP, Oberman HA, et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion 2001; 41: 1310-9.
49. Bordin JO, Bardossy L, Blaichman MA. Experimental animal model of refractoriness to donor platelets: the effect of plasma removal and the extent of white cell reduction on allogeneic alloimmunization. Transfusion 1993; 33: 798-801.
50. Wieding JU, Vehmeyer K, Dittman J, et al. Contamination of fresh-frozen plasma with viable white cells and proliferative stem cells [letter]. Transfusion 1994; 34: 185-6.
51. Willis JI, Lown JAG, Simpson MC, et al. White cells in fresh frozen plasma: evaluation of a new white cell-reduction filter. Transfusion 1998; 38: 645-9.
52. Stringham JC, Bull DA, Fuller TC, et al. Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. J Heart Lung Transplant 1999; 18:160-5.
53. Ohto H, Yasuda H, Yokota M, et al. HLA antibodies after transfusion of FFP [letter]. Transfusion 2000; 40: 613.
54. Hiruma K, Okuyama Y. Effect of leucocyte reduction on the potential alloimmunogenicity of leucocytes in fresh-frozen plasma products. Vox Sang 2001; 80: 51-6.
55. Chabanel A, Sensebé I, Masse M, et al. Quality assessment of seven types of fresh-frozen plasma leukoreduced by specific plasma filtration. Vox Sang 2003; 84: 308-17.
56. Burnouf T, Radosevich M, El-Ekiaby M, et al. Nanofiltration of single plasma donations: feasibility study. Vox Sang 2004; 84: 111-9.
57. Allain JP, Friedli H, Morgenthaler JJ, et al. International Forum: What are the critical factors in the production and quality control of frozen plasma intended for direct transfusion or for fractionation to provide medically needed labile coagulation factors? Vox Sang 1983; 44: 246-59.
58. Carlebjörk G, Blombäck M, Akerblom O. Improvement of plasma quality as raw material for factor VIII:C concentrates. Vox Sang 1983; 45: 233-42.
59. Kakaiya RM, Morse EE, Panek S. Labile coagulation factors in thawed fresh frozen plasma prepared by two methods. Vox Sang 1984; 46: 44-6.
60. Farrugia A, Hill R, Douglas S, et al. Factor VIII/von Willebrand factor levels in plasma frozen to -30°C in air or halogenated hydrocarbons. Thromb Res 1992; 68: 97-102.
61. Riggert J, Mörsdorf S, Pindur G, et al. Quality of fresh-frozen plasma during storage [letter]. Vox Sang 1997; 73: 257.
62. Myllylä G. Factors determining quality of plasma. Vox Sang 1998; 74 (Suppl. 2): 507-11.
63. Hellstern P, Bach J, Haubelt H, et al. The impact of the intensity of serial automated plasmapheresis and the speed of deep-freezing on the quality of plasma. Transfusion 2001; 41: 1601-5.
64. Ben-Tal O, Zwang E, Eichel R, et al. Vitamin K-dependent coagulation factors and fibrinogen levels in FFP remain stable upon repeated freezing and thawing. Transfusion 2003; 43: 873-7.
65. Burnouf T, Kappelsberger C, Frank K, et al. Protein composition and activation markers in plasma collected by three apheresis procedures. Transfusion 2003; 43: 1223-9.
66. Kretzschmar E, Kruse F, Greiss O, et al. Effects of extended storage of whole blood before leukocyte depletion on coagulation factors in plasma. Vox Sang 2004; 87: 156-64.
67. Runkel S, Haubelt H, Hitzler W, Hellstern P. The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood. Transfusion 2005; 45: 427-32.
68. Swärd-Nilsson AM, Persson PO, Johnson U, et al. Factors influencing factor VIII activity in frozen plasma. Vox Sang 2006; 90: 33-9.
69. Preston AE, Barr A. The plasma concentration of factor VIII in the normal population. The effect of age, sex and blood group. Br J Haematol 1964; 10: 238-45.
70. McCallum CJ, Peake IR, Newcombe RG, et al. Factor VIII levels and blood group antigens. Thromb Haemost 1983; 50: 757.
71. Mohanty D, Ghosh K, Marwaha N, et al. Major blood group antigens: a determinant of factor VIII levels in blood? Thromb Haemost 1984; 51: 414.
72. Ørstavik KH, Magnus P, Reisner H, et al. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Gen 1985; 37: 89-101.
73. Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
74. Shima M, Fujimura Y, Nishiyama T, et al. ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 1995; 68: 236-40.
75. Souto JC, Almasy L, Muòiz-Diaz E, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000; 20: 2024-8.
76. Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion 2001; 41: 56-60.
77. O'Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 2001; 11: 343-51.
78. O'Donnell J, Boulton FE, Manning RA, et al. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002; 22: 335-41.
79. Favaloro EJ, Soltani S, McDonald J, et al. Cross-laboratory audit of normal reference ranger and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. Blood Coagul Fibrinolysis 2005; 16: 597-605.
80. Sousa NC, Anichino-Bizzacchi JM, Locatelli MF, et al. The relationship between ABO blood groups and subgroups, factor VIII and von Willebrand factor. Haematologica 2007; 92: 2369.
81. Horowitz MS, Petha JC. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998; 74 (Suppl 1): 231-5.
82. Inbal A, Epstein O, Blickstein D, et al. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis 1993; 4: 599-604.
83. Santagostino E, Mancuso ME, Morfini M, et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica 2006; 91: 634-9.
84. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79: 826-31.
85. Santagostino E. Linee guida per la terapia sostitutiva dell'emofilia e dei difetti ereditari della coagulazione. Associazione Italiana dei Centri Emofilia, 2003. Available at: http://www.aiceonline.it/documenti/LineeGuida/ ITALIA_Coagulopatie.pdf.
86. United Kingdom Haemophilia Centre Doctors' Organization (UKHCDO). Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 1-23.
87. Bolton-Maggs PHB, Perry DJ, Chalmers EA, et al. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organization. Haemophilia 2004: 10: 593-628.
88. Norda R, Tynell E, Åkerblom O. Cumulative risks of early fresh frozen plasma, cryoprecipitate and platelet transfusion in Europe. J Trauma 2006; 60 (Suppl 6): S41-5.
89. MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. J Trauma 2006; 60 (Suppl 6): S46-50.
90. Domen RE, Hoeltge GA. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 2003; 127: 316-20.
91. Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent/detergent- treated frozen plasma. Transfusion 1998; 38: 102-7.
92. Allford SL, Hunt BJ, Rose P, Machin SJ, on behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-73.
93. Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003; 121: 778-85.
94. Yarranton H, Lawrie AS, Purdy G, et al. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004; 14: 39-44.
95. Brunskill SJ, Tusold A, Benjamin S, et al. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med 2007; 17: 17-35.
96. Nielsen HJ, Reimert C, Pedersen AN. Leucocyte-derived bioactive substances in fresh frozen plasma. Br J Anaesth 1997; 78: 548-52.
97. nd ed, Bethesda, MD: AABB Press; 2005. p. 541-78.
98. Baudoux E, Margraff U, Coenen A, et al. Hemovigilance: clinical tolerance of solvent-detergent treated plasma. Vox Sang 1998; 74 (Suppl 1); 237-9.
99. Wallis JP. Transfusion-related acute lung injury (TRALI) - under-diagnosed and under-reported [editorial]. Br J Anaesth 2003; 90: 773-6.
100. Silliman CJ, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101: 454-62.
101. Webert KE, Blajchman MA. Transfusion-related acute lung injury. Curr Opin Hematol 2005; 12: 480-7.
102. Gajic O, Gropper MA, Hubmayr RD. Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. Crit Care Med 2006: 34 (Suppl 5): S109-13.
103. Breanndan Moore S. Transfusion-related acute lung injury (TRALI): clinical presentation, treatment, and prognosis. Crit Care Med 2006: 34 (Suppl 5): S114-17.
104. Silliman CC. The two-event model of transfusion-related acute lung injury. Crit Care Med 2006: 34 (Suppl 5): S124-31.
105. Webert KE, Blajchman MA. Transfusion-related acute lung injury. Transfus Med Rev 2003; 17: 252-62.
106. Goldman M, Webert KE, Arnold DM, et al. Proceedings of a Consensus Conference: towards an understanding of TRALI. Transfus Med Rev 2005; 19: 2-31.
107. Curtis BR, McFarland JC. Mechanisms of transfusion-related acute lung injury (TRALI): anti-leukocyte antibodies. Crit Care Med 2006: 34 (Suppl 5): S118-23.
108. Zupanska B, Uhrynowska M, Michur H, et al. Transfusion-related acute lung injury and leucocyte-reacting antibodies. Vox Sang 2007; 93: 70-7.
109. Rasna R, Fernández-Pérez ER, Anjum Khan S, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion 2006; 46: 1478-83.
110. Engelfried CP, Reesink HW. International Forum: measures to prevent TRALI. Vox Sang 2007; 92: 258-77.
111. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007; 47: 599-607.
112. Mair DC, Hirschler N, Eastlund T. Blood donor and component management strategies to prevent transfusion-related acute lung injury (TRALI). Crit Care Med 2006; 34 (Suppl 5): S137-43.
113. Triulzi DJ, Kakaiya R, Schreiber G. Donor risk factors for white blood cell antibodies associated with transfusion-associated acute lung injury. REDS-II Leukocyte Antibody Prevalence Study (LAPS) [editorial]. Transfusion 2007; 47: 563-4.
114. Sinnott P, Bodger S, Gupta A, Brophy M. Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplasâ). Eur J Immunogenet 2004; 31: 271-4.
115. Sachs UJH, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 2005; 45: 1628-31.
116. Galbusera M, Noris M, Remuzzi G. Thrombotic thrombocytopenic purpura -then and now. Semin Thromb Hemost 2006; 32: 81-9.
117. Raife TJ. The changing paradigm of thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2005; 31: 641-51.
118. Raife TJ, Friedman KD, Dwyre DM. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura. Reconsideration of treatment with cryopoor plasma. Transfusion 2006; 46: 74-9.
119. Franchini M, Zafanello M, Veneri D. Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic sindrome. Thromb Res 2006; 118: 177-84.
120. Lian ECY. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Semin Thromb Hemost 2005; 31: 625-32.
121. Cataland SR, Wu HM. Immunotherapy for thrombotic thrombocytopenic pupura. Curr Opin Hematol 2005; 12: 359-63.
122. Heger A, Kannicht C, Römisch J, et al. Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplasâ) and in the universally applicable plasma (Uniplas) in development. Vox Sang 2007; 92: 206-12.
123. de la Rubia J, Arriaga F, Linares D, et al. Role of methylene blue-treated or fresh frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001; 114: 721-3.
124. Alvarez-Larrán A, Del Rio J, Ramírez C, et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004; 86: 246-51.
125. Rock G, Yousef H, Neurath H, et al. ADAMTS-13 in fresh, stored, and solvent/detergent-treated plasma [letter]. Transfusion 2006; 46: 1261-2.
126. Rock G, Yousef H, Neurath D, et al. ADAMTS-13 levels in fresh, stored, and solvent detergent treated plasma. Transfus Apher Sci 2006; 35: 235-8.
127. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 2004; 126: 213-8.
128. Scott EA, Puca KE, Pietz BC, et al. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 2007; 47: 120-5.
129. Franchini M. Thrombotic microangiopathies: an update. Hematology 2006; 11: 139-46.
130. Lowe EJ, Werner EJ. Thrombotic thrombocytopenic purpura and haemolytic uremic syndrome in children and adolescents. Semin Thromb Hemost 2005; 31: 717-29.
131. Harrison CN, Lawrie AS, Iobal A, et al. Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996; 94: 756-8.
132. Kentouche K, Budde U, Furlan M, et al. Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma. Acta Paediatr 2002; 91: 1056-9.
133. Barz D, Budde U, Hellstern P. Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes. Thromb Res 2002; 107: S23-7.
134. Fontana S, Kremer Hovinga JA, Studt JD, et al. Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Haematol 2004; 41: 48-59.
135. Chekrizova V, Murphy WG. Solvent-detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med 2006; 16: 85-91.
136. Tripodi G, Antoncecchi S, Fanetti G, et al. Recommendations on transfusion therapy in neonatology. Blood Transfus 2006; 4: 158-80.
137. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, et al. Are quality differences responsible for different adverse reaction reported for SD-plasma from USA and Europe? Transfus Med 2006; 16: 266-75.
138. de Jonge J, Groenland THN, Metselaar HJ, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP® ). Anesth Analg 2002; 94: 1127-31.
139. de Jonge J, Groenland THN, Metselaar HJ, et al [letter]. Liver transplantation, solvent-detergent treated plasma and antifibrinolytics. Anesth Analg 2003; 96: 1231-2.
140. Solheim BJ, Bergan A, Brosstad F, et al [letter]. Liver transplantation, solvent-detergent treated plasma and antifibrinolytics. Anesth Analg 2003; 96: 1230-1.
141. Freeman JW, Williamson LM, Llewelyn C, et al. A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during orthotopic liver transplantation. Vox Sang 1998; 74 (Suppl 1); 225-9.
142. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39: 1227-34.
143. Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent- treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002; 82: 9-14.
144. Beeck H, Hellstern P. In vitro characterization of solvent/detergent- treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998; 74 (Suppl 1): 219-23.
145. Mast AE, Stadanlick JE, Lockett JM, et al. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood 1999; 94: 3922-7.
146. Leebeek FWG, Schipperus MR, van Vliet HHDM. Coagulation factor levels in solvent/detergent-treated plasma [letter]. Transfusion 1999; 39: 1150-1.
147. Nifong T, Light J, Wenk RE. Coagulant stability and sterility of thawed S/D-treated plasma. Transfusion 2002; 42: 1581-4.
148. Solheim BJ, Hellstern P. Composition, efficacy and safety of S/D-treated plasma [letter]. Transfusion 2003; 43: 1176-8.
149. Doyle S, O'Brien P, Murphy K, et al. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 2003; 14: 283-7.
150. Flamholz R, Jeon HR, Baron JM, et al. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 2000; 15: 169-72.
151. Rizvi MA, Vesely JN, George JN, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura - haemolytic-uremic syndrome. Transfusion 2000; 40: 896-901.
152. McMinn JR Jr, Thomas IA, Terrel DR, et al. Complications of plasma exchange in thrombotic thrombocytopenic purpura -hemolytic uremic syndrome: a study of 78 additional patients [letter]. Transfusion 2003; 43: 415-6.